Erytech Pharma S.A.
We are a biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting both solid and liquid tumors for patients with high unmet medical needs. Our lead product candidate, which we refer to as eryaspase or GRASPA, targets the metabolism of cancers by depriving tumor cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells’ rapid growth rate.
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||Bâtiment Adénine, 60 Avenue Rockefeller, 69008 Lyon, France|
|Phone Number||+33 4 78 74 44 38|
|View Prospectus:||Erytech Pharma S.A.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-30.1 mil (last 12 months)|
|Price range||$0.00 - $0.00|
|Est. $ Volume||$100.0 mil|
|Manager / Joint Managers||Jefferies/ Cowen/ Oddo BHF|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|